RT期刊文章SR电子T1 24个月的锻炼改善帕金森病的运动症状(in6 - 2.005)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP in6 - OP in6 2.005 - 2.005 VO 78是1补充首页A1丹尼尔Corcos A1朱莉Robichaud A1 Fabian大卫A1瓦兰蔻A1辛西娅Poon A1米里亚姆拉弗蒂A1辛西娅·考米拉A1温迪Kohrt A1苏Leurgans年2012 UL //www.ez-admanager.com/content/78/1_Supplement/IN6-2.005.abstract AB目的:研究两种不同的运动干预的影响帕金森病(PD)超过24个月。主要终点是电机部分的统一帕金森病评定量表(UPDRS-III)。背景已经提出许多不同锻炼项目对PD患者,但很少有比较长时间。这个临床试验比较进步的阻力锻炼(前)与健康(FC)。之前的假设是将改善UPDRS-III在更大程度上与FC由于程序的进步和自然更强烈。设计/方法:这是一个24个月,blinded-rater,随机对照临床试验。参与者基于性别配对,off-medication UPDRS-III得分。在一对,作业前或FC是随机的。UPDRS-III服用了药物在基线,6、12、18和24个月的运动。参与者运动一小时,每周两次为24个月。结果:48参与者(58%的男性,年龄= 59岁,疾病持续时间= 7年)完成了六个月的计划,与38完成24个月。 The mean UPDRS-III score off medication decreased for both FC (-5.38) and PRE (-6.42) from baseline to six months (p's < .0001); these changes did not differ by group (p = .5467). In contrast, the UPDRS-III score was reduced for PRE compared with FC at 12 months (p = .023), 18 months (p = 0.017) and 24 months (p <.001). At 24 months the UPDRS-III score for the FC group had returned to baseline whereas the PRE group maintained a 7.3 point improvement.Conclusions: Both PRE and FC reduced UPDRS-III score in PD following the six-month intervention, but PRE was significantly better over two years. Improved motor status over 24 months in a progressive neurodegenerative disease suggests that long-term PRE could be considered an integral component of comprehensive disease management.Supported by: 2RO1 NS028127-15.Disclosure: Dr. Corcos has nothing to disclose. Dr. Robichaud has nothing to disclose. Dr. David has nothing to disclose. Dr. Vaillancourt has received personal compensation from Clevemed as a consultant. Dr. Poon has nothing to disclose. Dr. Rafferty has received personal compensation for activities with Rehabilitation Institute of Chicago (RIC) Academy and Creative Therapy Resources as a speaker and consultant. Dr. Comella has received personal compensation for activities with Ipsen, Merz Pharma, Allergan, Inc., and NuPathe. Dr. Comella has received research support from Ipsen, Merz Pharma, Allergan, Inc., the National Institutes of Health, and the Dystonia Study Group. Dr. Kohrt has nothing to disclose. Dr. Leurgans has nothing to disclose.Monday, April 23 2012, 14:00 pm-18:00 pm